CENTURY(SZ:300078) 2 1 Shi Ji Jing Ji Bao Dao·2025-08-18 00:44Policy Developments - The National Healthcare Security Administration (NHSA) has issued the "Interim Measures for the Management of Disease-Specific Payment" to promote a multi-faceted healthcare payment reform focused on disease-specific payments [1][2] - The framework consists of eight chapters and thirty-nine articles, emphasizing budget management, grouping scheme formulation, and core elements and supporting measures [2][3] - The introduction of this measure is expected to enhance the standardization of disease-specific payment systems and improve the efficiency of healthcare fund utilization [3] Drug and Medical Device Approvals - Kehua Bio's syphilis antibody quality control product has received a medical device registration certificate, which will enhance the company's product line [4] - Haikang Pharmaceutical's new indication application for HSK39297 tablets has been accepted, targeting age-related macular degeneration and generalized myasthenia gravis [5] Financial Reports - Leksin Medical reported a revenue of 521 million yuan for the first half of the year, a year-on-year increase of 4.57%, with a net profit of 42.29 million yuan, up 21.35% [6] - Gilead Sciences reported a revenue of 104 million yuan for the first half of the year, a significant increase of 111.4%, with a net loss of 87.95 million yuan, narrowing by 32.5% [7] Mergers and Acquisitions - Yunnan Baiyao plans to acquire 100% equity of Juyitang Pharmaceutical for 660 million yuan to enhance its business layout and expand its market presence [8] - Kangzhong Medical intends to invest 20 million yuan to acquire a 6.67% stake in Shanghai Renyan Information Technology to support its strategic transformation [9] Industry Events - Ji Xunming has been appointed as the president of the Chinese Academy of Medical Sciences and Peking Union Medical College [10] - The National Health Commission and the Ministry of Education are urging Beijing Union Medical College to rectify issues related to its "4+4" pilot program [11] Other Developments - Buchang Pharmaceutical's subsidiary plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine for 15 million yuan [12] - Zhongke Investment plans to reduce its stake in Nanwei Medical by up to 2% due to funding needs [13] - Sichuan Medical Technology has received a notice from the Hangzhou Public Security Bureau regarding evidence collection related to a securities fraud investigation [14]